Psyence BioMed forms Texas entity for U.S. ibogaine research

Psyence Biomedical Ltd. has announced the creation of the Texas Ibogaine Research Corporation (TIRC), a new entity designed to streamline the company's ibogaine development activities in the United States. This move aims to consolidate efforts in pharmaceutical-grade supply, regulatory engagement, and potential clinical development, according to a recent report by RTT News.

U.S. Ibogaine Development Strategy

TIRC is set to act as Psyence BioMed's central U.S. hub for regulated ibogaine development. The entity will manage licensing, manufacturing, regulatory, and clinical activities, all under a single organizational structure. Subject to finalizing licensing agreements, TIRC will hold the U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, a company specializing in neuroplastogen active pharmaceutical ingredients in which Psyence BioMed has a stake.

The company plans for TIRC to oversee rights coordination, manufacturing arrangements, and regulatory documentation, as well as any future investigational new drug applications. TIRC will also engage with federal agencies, state programs, and potential clinical partners in the U.S.

Leadership and Support

Jody Aufrichtig, CEO of Psyence BioMed, will also lead TIRC, with Dr. John Thorne appointed as the project lead. The company will provide technical, legal, administrative, and financial support through its internal resources, with oversight from CFO Warwick Corden-Lloyd and the in-house legal team.

Regulatory and Research Developments

The establishment of TIRC follows recent U.S. policy and research developments related to neuroplastogens, including ibogaine. Notable developments include an Executive Order issued on April 18, 2026, directing federal agencies to expedite relevant research, and a coordinated federal implementation announced in July 2026. Additionally, the University of Miami's original 1994 ibogaine investigational new drug application has been provided to the U.S. Department of Health and Human Services.

Next Steps

Psyence BioMed's next steps involve finalizing licensing arrangements, advancing regulatory engagement, and developing manufacturing and clinical plans to support a potential U.S. ibogaine development program. These plans are contingent upon applicable laws, regulatory requirements, and the availability of suitable development pathways.

Why It Matters

The formation of TIRC represents a strategic move by Psyence BioMed to advance ibogaine research and development in the U.S., a market with growing interest in alternative treatments for conditions like opioid use disorder and PTSD. By establishing a dedicated entity, the company aims to streamline its efforts and capitalize on evolving regulatory landscapes.

Psyence BioMed's stock has fluctuated between $1.92 and $216.41 over the past year, closing at $5.40 on September 11, 2026, and rising slightly in pre-market trading.